G-SOX

JapicCTI-101021 📎

Regimen

Experimental
S-1 + oxaliplatin 100 mg/m2 d1 Q3W (SOX)
Control
S-1 + cisplatin 60 mg/m2 d8 Q5W (CS)

Population

Japanese chemotherapy-naive advanced gastric cancer

Key finding

mOS 14.1 vs 13.1 mo; PFS HR 1.004 (noninferior); SOX fewer grade>=3 AEs (less renal, less neutropenia)

Source: PMID 25316259

Timeline

    Guideline citations

    • NCCN GASTRIC (p.122)
    • CSCO GASTRIC 2025 (p.64)⚠️ OCR source